Scholar Rock is preparing to launch apitegromab, the first therapy targeting muscles for spinal muscular atrophy (SMA), pending FDA approval expected by September 30, 2026. Manufacturing delays have been due to production issues, not drug safety or efficacy, with alternative facilities reducing but not eliminating approval risks. Clinical trial data from the SAPPHIRE study show apitegromab improves motor function significantly in nonambulatory SMA patients when added to existing treatments. The company's valuation heavily depends on this drug's approval and commercial success, with risks tied to regulatory and market execution.
AMD reported impressive AI-driven earnings with Data Center revenue doubling and strong margin expansion, yet its stock price fell due to concerns over product mix and margin pressure. Despite a recent sideways stock movement, analysts remain bullish...
Hunter Biden announced the launch of a new memecoin called LAPTOP, set to debut on September 9 on Coinbase's Base network. The token aims to engage holders who lost money on the Trump memecoin by reserving 200 million tokens for airdrops to them and ...
Analyst Dr. Kamilah Stevenson warns XRP investors that even if they are right about the asset's long-term potential, mistiming market events like adoption or regulation can lead to losses. She highlights that many key factors influencing XRP's succes...
Mayan Finance has facilitated over $20.23 billion in cross-chain swaps using Wormhole's technology, processing 9.6 million transactions from 3.4 million unique wallets. The protocol offers fast transaction times of 2 to 12 seconds and low fees, with ...
Dogecoin (DOGE) has been fully integrated onto the Solana blockchain through Wormhole's Native Token Transfers (NTT) framework and the Sunrise liquidity gateway. This integration, covering DOGE's entire $35 billion circulating supply, allows DOGE to ...
